ARTICLE | Company News
Biogen Idec, NsGene deal
August 16, 2010 7:00 AM UTC
The partners granted Biogen Idec exclusive, worldwide rights to develop and commercialize Neublastin artemin/enovin for all indications under an amended 2000 deal that granted Biogen Idec rights to Ne...